Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

Novo Nordisk's competition in the obesity drug market is heating up.Novo Nordisk's (NVO -0.54%) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping position is precarious. Here are three drugs most likely to dethrone Novo Nordisk's blockbuster drug.1. Eli Lilly's Zepbound/MounjaroEli Lilly (LLY 1.85%) won U.S. regulatory approval for Ze ...